A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing based on participant self-reporting * Body mass index (BMI) ≥18.0 and ≤32.0 kg/m\^2 * Able to swallow multiple tablets Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * History or presence of any of the following: * Adrenal insufficiency * Hepatic or renal impairment * Gallstones, hepatitis disease, or hepatic porphyrias * Psychosis * Clinically significant hypotension, cardiac arrhythmia, cardiac conduction abnormalities, or recurrent unexplained syncopal events * Second- or third-degree atrioventricular heart block * Clinically significant sick sinus syndrome * Recurrent seizures, increased risk for seizures, or myasthenia gravis * Clinically significant hematologic disorders/blood dyscrasias, including adverse hematologic reactions to any drugs or experimental therapies * Any systemic fungal infection * Chronic infection * Glaucoma * Hypothyroidism * Unexplained electrolyte abnormalities, current hyponatremia, diuretic use, or syndrome of inappropriate antidiuretic hormone secretion (siADH) * Severe dermatologic reaction * Stomach ulcer * Has a first-degree relative with multiple unexplained syncopal events, unexplained cardiac arrest, or sudden cardiac death, or has a known family history of an inherited arrhythmia syndrome (including Brugada syndrome) * History of cancer (malignancy) * Unable to refrain from or anticipates the use of: Any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to the first dosing